EGFR and neoplasm: By binding with tyrosine kinase, EGFR TKIs can inhibit the activation of tyrosine kinase and block downstream signaling pathways, ultimately inhibiting the proliferation and metastasis of tumor cells and promoting the apoptosis of tumor cells.